Recombinant human brain natriuretic peptide(Shandong Danhong Pharmaceutical)

Primary objectives: 1) To evaluate the safety and tolerability of BC003 in patients with acute decompensated heart failure (ADHF) with dyspnea at rest or with minimal activity; 2) To explore the maximum tolerated dose (MTD) of BC003 in patients with acute decompensated heart failure (ADHF) with dyspnea at rest or with minimal activity. Secondary objectives: 1) To evaluate the pharmacokinetic (PK) characteristics of BC003 in patients with acute decompensated heart failure (ADHF) with dyspnea at rest or with minimal activity; 2) To explore the preliminary efficacy of BC003 in patients with acute decompensated heart failure (ADHF) with dyspnea at rest or with minimal activity. Exploratory objectives: 1) To evaluate the correlation between BC003 blood concentration and heart rate-corrected QT interval (QTc) and electrocardiogram (ECG) parameters in patients with acute decompensated heart failure (ADHF) who have dyspnea at rest or during mild activity; 2) To obtain the drug concentration-effect range through quantitative pharmacology modeling, determine the effective drug concentration range, and explore the correlation between PK, efficacy, and safety.